NCT00497497View on ClinicalTrials.gov

A Study of PRO95780 in Combination With Cetuximab and Irinotecan Chemotherapy or the FOLFIRI Regimen With Bevacizumab in Patients With Previously Treated Metastatic Colorectal Cancer (APM4187g)

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

September 30, 2010

Study Completion Date

September 30, 2010

Conditions
Colorectal Cancer
Interventions
DRUG

bevacizumab

(Only for patients not previously treated with bevacizumab) Intravenous repeating dose

DRUG

cetuximab

Intravenous repeating dose

DRUG

FOLFIRI regimen

Intravenous repeating dose

DRUG

irinotecan

Intravenous repeating dose

DRUG

PRO95780

Intravenous repeating dose

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY

NCT00497497 - A Study of PRO95780 in Combination With Cetuximab and Irinotecan Chemotherapy or the FOLFIRI Regimen With Bevacizumab in Patients With Previously Treated Metastatic Colorectal Cancer (APM4187g) | Biotech Hunter | Biotech Hunter